Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Astria Therapeutics, retaining the price target of $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors related to Astria Therapeutics’ promising clinical data and potential market advantages. The initial results from the Phase 1a trial of Astria’s STAR-0310, an anti-OX40 monoclonal antibody, show promising safety and efficacy profiles. The data indicates that STAR-0310 may offer a wider therapeutic window compared to first-generation OX40 antibodies, such as Amgen’s rocatinlimab, due to its lower antibody-dependent cell-mediated cytotoxicity and absence of dose-limiting adverse effects.
Moreover, the potential for a best-in-class dosing profile, with a demonstrated 68-day half-life, suggests that STAR-0310 could support a convenient biannual subcutaneous dosing regimen. These attributes not only enhance the drug’s safety profile but also its market competitiveness, making it a compelling candidate for further development in treating inflammatory and immunological conditions. These factors collectively underpin Slutsky’s positive outlook and Buy rating for Astria Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.